Navigation Links
Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
Date:12/4/2008

MENLO PARK, Calif., Dec. 4 /PRNewswire/ -- Long-term data published in EuroIntervention showed that the expected decrease in Mitral Vale Area (MVA) after repair with the MitraClip(R) system to correct mitral regurgitation (MR) is not associated with clinically significant mitral stenosis. Additionally, with two years of follow-up, none of the patients treated with the MitraClip(R) system required surgery for mitral stenosis. At 12 months no important differences were reported between the use of one or two MitraClip(R) devices or based on the etiology of MR.

The analysis was conducted to assess diastolic mitral valve function after percutaneous repair. Echocardiographic measurements of MVA and mean trans- Mitral Valve Gradient (MVG) were made in 96 patients implanted with the MitraClip(R) device. Patients were followed for up to two years.

The MitraClip(R) system is the first commercially available medical device which provides a non-surgical mitral valve repair option for patients suffering from the effects of MR. The MitraClip(R) system is available commercially in Europe and is currently in late stage clinical trials in the United States.

MR affects millions of people worldwide and is the most common type of heart valve insufficiency in Europe and in the United States. The vast majority of patients with significant MR are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

"It is important to know that the encouraging results from use of the MitraClip(R) system were maintained at two years without mitral stenosis," said Howard C. Herrmann, M.D., director, Interventional Cardiology and Cardiac Catheterization Laboratories at the hospital of the University of Pennsylvania and lead author of the manuscript. "With these results, we have a growing body of evidence that MitraClip(R) therapy can be a good option for many patients in the right situation."

The MitraClip device creates a double orifice mitral valve by securing the leaflets to reduce MR in a replication of the surgical procedure pioneered by Ottavio Alfieri, MD. The resulting double orifice has an inherently smaller cross sectional area compared to the native mitral valve. In a preliminary study published in Catheterization and Cardiovascular Interventions in 2006, Dr. Herrmann and colleagues demonstrated a similar decrease in MVA using the MitraClip(R) system also without causing mitral stenosis. In the present analysis, these observations were extended to a larger study population with longer term follow up, and included patients who received more than one MitraClip(R) device and those with functional MR.

The study population for the present analysis included 107 patients with moderate-to-severe or severe MR who were enrolled in the EVEREST phase I registry (n=55) or subjects who were not randomized as part of the EVEREST II trial (n=52).

Baseline characteristics and hemodynamic measurements were analyzed for the 96 patients in the study population who received the MitraClip(R) device. All patients were either symptomatic (91 percent) or if asymptomatic had evidence of left ventricular dysfunction.

Transthoracic echocardiography was performed at baseline, pre-discharge, one year and two year follow-up and analyzed by an independent core echocardiographic laboratory at the University of California at San Francisco.

The mean MVA as measured by planimetry decreased from 6.0 +/- 1.3 cm at baseline to 3.6 +/-1.2 cm (p<0.05) at discharge. At 12 months MVA was 3.6 +/- 1.2 cm (n= 59). The mean MVG increased from 1.7 +/- 0.9 mmHg at baseline to 4.1 +/-2.2 mmHg (p<0.05) at discharge. At 12 months MVG was 3.4 +/-1.6 mmHg (n=50). From discharge to 24 months, there were no significant changes in the mean MVA or MVG. There were no differences in mean MVA or MVG at 12 month follow up between patients who received one MitraClip(R) device (69 percent) and those receiving two MitraClip(R) devices (31 percent). Patients with functional MR had a slightly smaller mean MVA, both at baseline and at discharge, but did not differ from degenerative MR patients at later follow- up. These hemodynamic results are consistent with reports of surgical edge-to- edge repair which also have shown that diastolic mitral valve function is preserved.

"These longer-term results contribute to the existing body of clinical data regarding the performance of this first in class, less invasive treatment approach. We are pleased that Dr. Hermann and the coauthors have reported this important information so that it is available for physicians to discuss with their patients as they consider this non-surgical treatment option" said Ferolyn Powell, president and chief executive officer of Evalve.

About the MitraClip(R) Procedure

Percutaneous mitral repair with Evalve's MitraClip(R) system is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) therapy may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc. -headquartered in Menlo Park, California- has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (www.thefoundry.com).

The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada.

MitraClip(R) and Evalve are registered trademarks of Evalve, Inc.


'/>"/>
SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
4. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
5. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):